

Investment objective

Aims to achieve a long-term total return (before fees and expenses) that exceeds the MSCI World ex Australia Index, in \$A unhedged with net dividends reinvested (**Benchmark**).

Key information

Fund details

APIR code	MAQ0838AU
Inception date	10 October 2014
Investment manager	Polaris Capital Management, LLC (Boston, US)
Fund size	\$250.0m
Distribution frequency	Semi-annually
Management fee*	1.28% pa
Minimum investment (Direct)	\$5,000
Unit prices and spreads	macquarie.com.au/unit_prices

*Read the Product Disclosure Statement for more details on fees and costs.

Fund performance to 31 August 2021

	Total Fund return (gross)	Total Fund return (net)	Benchmark return	Total excess return (net)
1 month (%)	2.53	2.42	3.10	-0.68
3 months (%)	4.07	3.74	12.31	-8.57
1 year (%)	44.19	42.41	31.37	11.04
3 years (% pa)	9.48	8.09	14.67	-6.58
5 years (% pa)	12.08	10.66	15.58	-4.92
Since inception (% pa)	13.20	11.77	15.11	-3.34

Past performance is not a reliable indicator of future performance.

Total returns are calculated based on changes in net asset values and assumes the reinvestment of distributions.

Total net Fund returns are quoted after the deduction of fees and expenses. Due to individual circumstances, your net returns may differ from the net returns quoted above.

Top 10 stocks


Stock	Sector	Industry	Holding (%)
Crocs Inc	Consumer discretionary	Textiles Apparel & Luxury Goods	2.13
Capital One Financial Corp	Financials	Consumer Finance	1.73
United Therapeutics Corp	Health care	Biotechnology	1.68
Jpmorgan Chase & Co	Financials	Banks	1.51
Publicis Groupe Sa	Communication services	Media	1.50
Marathon Petroleum Corp	Energy	Oil Gas & Consumable Fuels	1.47
Popular Inc	Financials	Banks	1.46
Kia Corporation	Consumer discretionary	Automobiles	1.45
Webster Financial Corp	Financials	Banks	1.36
Mondi Plc	Materials	Paper & Forest Products	1.35
Total number of stocks			96

Polaris Global Equity Fund

Macquarie Professional Series

Monthly report – 31 August 2021

Growth of \$100,000 since inception




Past performance is not a reliable indicator of future performance.

Sector weights

Sector	Fund (%)	Benchmark (%)
Financials	20.31	12.97
Consumer discretionary	16.15	11.81
Materials	12.40	4.02
Health care	9.93	12.83
Industrials	9.15	10.52
Information technology	8.12	23.24
Communication services	7.57	9.42
Consumer staples	5.37	6.94
Energy	2.48	2.78
Utilities	1.87	2.80
Real estate	0.93	2.65
Cash	5.73	0.00
Total	100	100


Sector attribution (12 months to date)



Region weights

Region	Fund (%)	Benchmark (%)
North America	42.78	72.62
Europe ex UK	20.64	15.15
Emerging Markets	11.08	0.00
United Kingdom	10.60	4.20
Japan	8.37	6.77
Asia ex Japan	0.81	1.27
Cash	5.73	0.00
Total	100	100

Region attribution (12 months to date)




Polaris Global Equity Fund

Macquarie Professional Series

Monthly report – 31 August 2021

Market capitalisation



Performance summary

- The Fund returned 2.42% in August 2021, compared with a return for the Benchmark of 3.10%, with global equity markets achieving a further consecutive month of gains.
- All GICS sectors with the exception of Energy moved higher in August. For the Fund, the largest sector detractors on a relative basis were holdings in IT, which lagged the rise of the broader sector, and an underweight to the sector, as well as holdings in Materials, including Lundin Mining and Lanxess, and an overweight to the sector. These results were partially offset by overweight positioning and holdings in Financials, such as Bancolombia.
- United Therapeutics and Babcock International were among the top individual contributors to performance in August. United Therapeutics beat analyst estimates for both revenue and earnings for the second quarter, and the company continued its expansion of Tyvaso into new applications beyond pulmonary arterial hypertension. Babcock International, which provides engineering support services to the UK defence sector, bounced back after reassuring the market in its annual results announcement that it does not need to raise equity, and is expecting improved sales growth.
- Jazz Pharmaceuticals and LG Electronics were among the top individual detractors from performance in August. Jazz's launch of Xywav, a prescription medicine used to treat narcolepsy symptoms and idiopathic hypersomnia, has outperformed estimates four quarters in a row, resulting in the sooner-than-expected launch of authorised generics against Xywav's precursor Xyrem. Although LG announced its highest quarterly revenues ever in second quarter, with the company continuing to expand its market share in premium home appliances and consumer electronics outside of South Korea, profits in two of its divisions fell.
- During the month, Polaris completed the initial purchases of LG Electronics (LGE) and Discovery. LGE is a global leader in home appliances and continues to take market share from existing powerhouses such as Whirlpool and Electrolux. LGE has elevated its brand equity, targeted the premium market, and introduced new appliance segments, resulting in a massive improvement in the profitability of their appliance business over the past decade. Discovery, a US content developer and distributor, has a differentiated content portfolio and its merger with Warner Media will give it the scale to compete with larger peers. Polaris also completed the final sales of US regional bank Ameris Bancorp, diversified chemical company Lanxess and pulp machinery maker Valmet, all on valuation grounds.

For more information speak to your financial adviser, call us on 1800 814 523, email mim.clientservice@macquarie.com or visit macquarie.com

Important information

Weights and attribution breakdown for sector, stocks and region are sourced from Macquarie and Factset.

Macquarie Investment Management Australia Limited ABN 55 092 552 611 AFS Licence 238321 is the issuer of units in, and responsible entity of the Fund.

The information in this report is provided for general information purposes only and is not, and should not be construed as, an advertisement, an invitation, an offer, a solicitation of an offer or a recommendation to participate in any investment strategy or take any other action, including to buy or sell any product offered by any member of the Macquarie Group. The above information is not personal advice and does not take into account the investment objectives, financial situation or needs of any person. Investors should consider the offer document of the Fund in deciding whether to acquire or continue to hold units in the Fund. The offer document is available by contacting us on 1800 814 523. Past performance is not a reliable indicator of future performance.

Future results are impossible to predict. In preparing this document, reliance may have been placed, without independent verification, on the accuracy and completeness of information available from external sources. This report may also include opinions, estimates and other forward-looking statements which are, by their very nature, subject to various risks and uncertainties. Actual events or results may differ materially, positively or negatively, from those reflected or contemplated in such forward-looking statements. Forward-looking statements constitute the investment manager's judgement as at the date of preparation of this report and are subject to change without notice. To the maximum extent permitted by law, no member of the Macquarie Group nor its directors, employees or agents accept any liability for any loss arising from the use of this document, its contents or otherwise arising in connection with it.

Other than Macquarie Bank Limited (MBL), none of the entities noted in this document are authorised deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia). The obligations of these entities do not represent deposits or other liabilities of MBL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of these entities, unless noted otherwise.